Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia

Bibliography

• Hallek M, Cheson BD, Catovsky D, Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-56
   PubMed Web of Science ®Google Scholar
• Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 2011;25:13-25
   PubMed Web of Science ®Google Scholar
• Nadler LM, Ritz J, Hardy R, A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981;67:134-40
   PubMed Web of Science ®Google Scholar
• Alduaij W, Illidge TM. The future of anti-CD20 monoclonal antibodies: are we making progress? Blood 2011;117:2993-3001
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Wierda W, Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-80
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-74
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-55
   PubMed Web of Science ®Google Scholar
• Robak T. Rituximab for chronic lymphocytic leukemia. Expert Opin Biol Ther 2012;12:503-15
   PubMed Web of Science ®Google Scholar
• Riaz W, Hernandez-Ilizaliturri FJ, Czuczman MS. Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunol Res 2010;46:192-205
   Google Scholar
• Deans JP, Polyak MJ. FMC7 is an epitope of CD20. Blood 2008;111:2492; author reply 3-4
   PubMed Web of Science ®Google Scholar
• Delgado J, Matutes E, Morilla AM, Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. Am J Clin Pathol 2003;120:754-9
   PubMed Web of Science ®Google Scholar
• Beers SA, Chan CH, French RR, CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010;47:107-14
   PubMed Web of Science ®Google Scholar
• Deans JP, Kalt L, Ledbetter JA, Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995;270:22632-8
   PubMed Web of Science ®Google Scholar
• Popoff IJ, Savage JA, Blake J, The association between CD20 and Src-family Tyrosine kinases requires an additional factor. Mol Immunol 1998;35:207-14
   PubMed Web of Science ®Google Scholar
• Cragg MS. CD20 antibodies: doing the time warp. Blood 2011;118:219-20
   Google Scholar
• O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics 1998;48:125-32
   PubMed Web of Science ®Google Scholar
• Uchida J, Lee Y, Hasegawa M, Mouse CD20 expression and function. Int Immunol 2004;16:119-29
   PubMed Web of Science ®Google Scholar
• Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 2010;28:3525-30
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71
   PubMed Web of Science ®Google Scholar
• Rossmann ED, Lundin J, Lenkei R, Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001;2:300-6
   PubMedGoogle Scholar
• Di Gaetano N, Cittera E, Nota R, Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-7
   PubMed Web of Science ®Google Scholar
• Beers SA, Chan CH, James S, Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008;112:4170-7
   PubMed Web of Science ®Google Scholar
• Tawara T, Hasegawa K, Sugiura Y, Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J Immunol 2008;180:2294-8
   PubMed Web of Science ®Google Scholar
• Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008;111:1456-63
   PubMed Web of Science ®Google Scholar
• Bannerji R, Kitada S, Flinn IW, Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003;21:1466-71
   PubMed Web of Science ®Google Scholar
• Uchida J, Hamaguchi Y, Oliver JA, The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199:1659-69
   PubMed Web of Science ®Google Scholar
• Farag SS, Flinn IW, Modali R, Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004;103:1472-4
   PubMed Web of Science ®Google Scholar
• Ivanov A, Beers SA, Walshe CA, Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009;119:2143-59
   PubMed Web of Science ®Google Scholar
• Abes R, Gelize E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010;116:926-34
   PubMed Web of Science ®Google Scholar
• Dalle S, Reslan L, Besseyre de Horts T, Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011;10:178-85
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HT, Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101:1045-52
   PubMed Web of Science ®Google Scholar
• Chan HT, Hughes D, French RR, CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003;63:5480-9
   PubMed Web of Science ®Google Scholar
• Ivanov A, Krysov S, Cragg MS, Illidge T. Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res 2008;14:4925-34
   PubMed Web of Science ®Google Scholar
• Nishida M, Uematsu N, Kobayashi H, BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties. Int J Oncol 2011;38:335-44
   PubMed Web of Science ®Google Scholar
• Goteri G, Olivieri A, Ranaldi R, Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome. Int J Immunopathol Pharmacol 2006;19:421-31
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Olejniczak S, Gowda A, Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008;14:1561-70
   PubMed Web of Science ®Google Scholar
• Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol 2011;24:203-16
   PubMed Web of Science ®Google Scholar
• Hiraga J, Tomita A, Sugimoto T, Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009;113:4885-93
   PubMed Web of Science ®Google Scholar
• Beum PV, Kennedy AD, Williams ME, The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006;176:2600-9
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115:5191-201
   PubMed Web of Science ®Google Scholar
• Williams ME, Densmore JJ, Pawluczkowycz AW, Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006;177:7435-43
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45
   PubMed Web of Science ®Google Scholar
• Niitsu N, Hagiwara Y, Tanae K, Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010;28:5097-100
   PubMed Web of Science ®Google Scholar
• Ram R, Ben-Bassat I, Shpilberg O, The late adverse events of rituximab therapy–rare but there! Leuk Lymphoma. 2009;50:1083-95
   Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA, IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95
   PubMed Web of Science ®Google Scholar
• Nguyen DT, Amess JA, Doughty H, IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999;62:76-82
   PubMed Web of Science ®Google Scholar
• Almasri NM, Duque RE, Iturraspe J, Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992;40:259-63
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS, Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-64
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian H, Thomas DA, Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-70
   PubMed Web of Science ®Google Scholar
• Thomas DA, O'Brien S, Giles FJ, Single agent rituxan in early stage chronic lymphocytic leukemia(CLL) [abstract]. Blood 2001;98:364
   Google Scholar
• Hainsworth JD, Litchy S, Barton JH, Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746-51
   PubMed Web of Science ®Google Scholar
• Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001;7:709-23
   PubMed Web of Science ®Google Scholar
• Schulz H, Klein SK, Rehwald U, Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100:3115-20
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Del Principe MI, Consalvo MA, The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer 2005;104:2743-52
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA, Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14
   PubMed Web of Science ®Google Scholar
• Byrd JC, Rai K, Peterson BL, Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 2011;29:1349-55
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001;7:3580-9
   PubMed Web of Science ®Google Scholar
• Molica S, Digiesi G, Battaglia C, Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. Eur J Haematol 2010;85:314-20
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88
   PubMed Web of Science ®Google Scholar
• Bottcher S, Ritgen M, Fischer K, Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012;30:980-8
   PubMed Web of Science ®Google Scholar
• Foon KA, Boyiadzis M, Land SR, Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:498-503
   PubMed Web of Science ®Google Scholar
• Foon KA, Mehta D, Lentzsch S, Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood 2012;119:3184-5
   PubMed Web of Science ®Google Scholar
• Lamanna N, Jurcic JG, Noy A, Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009;27:491-7
   PubMed Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG, Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405-11
   PubMed Web of Science ®Google Scholar
• Bosch F, Abrisqueta P, Villamor N, Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009;27:4578-84
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30(26):3209-16
   PubMed Web of Science ®Google Scholar
• Foa R, Ciolli S, Raimondo FD, Rituximab plus chlorambucil as initial treatment for elderly patients with chronic lymphocytic leukemia (CLL): effect of pre-treatment biological characteristics and gene expression patterns on response to treatment [abstract]. Blood 2011;118:1
   PubMedGoogle Scholar
• German CLL Study Group NCIN, ClinicalTrials.gov NCT00769522. Fludarabine, Cyclophosphamide, and Rituximab or Bendamustine and Rituximab in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. Available from: http://clinicaltrialsgov/ct2/results?term=NCT00769522 2012
   Google Scholar
• Parikh SA, Keating MJ, O'Brien S, Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011;118:2062-8
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kipps TJ, Flinn IW, Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;115:489-95
   PubMed Web of Science ®Google Scholar
• Reynolds C, Di Bella N, Lyons RM, A phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs 2012;30:1232-40
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-65
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559-66
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wang X, Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011;117:3016-24
   PubMed Web of Science ®Google Scholar
• Lamanna N, Kalaycio M, Maslak P, Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24:1575-81
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P, Cebula B, Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006;107:1542-50
   PubMed Web of Science ®Google Scholar
• Castro JE, James DF, Sandoval-Sus JD, Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009;23:1779-89
   PubMed Web of Science ®Google Scholar
• Dungarwalla M, Evans SO, Riley U, High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008;93:475-6
   PubMed Web of Science ®Google Scholar
• Bowen DA, Call TG, Jenkins GD, Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48:2412-17
   PubMed Web of Science ®Google Scholar
• Pileckyte R, Jurgutis M, Valceckiene V, Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leuk Lymphoma 2011;52:1055-65
   PubMed Web of Science ®Google Scholar
• Smolej L, Doubek M, Panovska A, Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. Leuk Res 2012;36:1278-82
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42-51
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Del Principe MI, Buccisano F, Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008;112:119-28
   PubMed Web of Science ®Google Scholar
• Bosch F, Abrisqueta P, Villamor N, Rituximab maintenance in patients with chronic lymphocytic leukemia (CLL) after upfront treatment with rituximab plus fludarabine, cyclophosphamide, and mitoxantrone (R-FCM): final results of a multicenter phase II trial on behalf of the Spanish CLL study group (GELLC) [abstract]. Blood 2011;118:293
   Google Scholar
• Zaja F, Vianelli N, Sperotto A, Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003;44:1951-5
   PubMed Web of Science ®Google Scholar
• Kaufman M, Limaye SA, Driscoll N, A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:892-9
   PubMed Web of Science ®Google Scholar
• Rossignol J, Michallet AS, Oberic L, Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia 2011;25:473-8
   PubMed Web of Science ®Google Scholar
• Bowen DA, Call TG, Shanafelt TD, Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma 2010;51:620-7
   PubMed Web of Science ®Google Scholar
• Sharman J, de Vos S, Leonard JP, A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [abstract]. Blood 2011;118:1787
   Google Scholar
• Badoux X, Keating M, O'Brien S, Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [abstract]. Blood 2011;118:980
   Google Scholar
• Wierda W, Balakrishnan K, Ferrajoli A, A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL [abstract]. Blood 2011;118:3901
   PubMedGoogle Scholar
• Teeling JL, French RR, Cragg MS, Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-800
   PubMed Web of Science ®Google Scholar
• Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol 2012;156:490-8
   PubMed Web of Science ®Google Scholar
• Li B, Zhao L, Guo H, Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009;114:5007-15
   PubMed Web of Science ®Google Scholar
• Bleeker WK, Munk ME, Mackus WJ, Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 2008;140:303-12
   PubMed Web of Science ®Google Scholar
• Haskova Z, Whitacre MN, Dede KA, Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia. Br J Haematol 2012;156:402-4
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094-100
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts; 2010. p. 116
   Google Scholar
• Wierda WG, Gupta IV. Steen Lisby and Anders Osterborg on behalf of the Hx-CD20-406 Study Investigators. Pretreatment Characteristics Correlated with Outcomes in Patients with Fludarabine-Refractory CLL Treated With Ofatumumab: Final Response Analysis. Lugano Abstract; 2011
   Google Scholar
• Wierda WG, Padmanabhan S, Chan GW, Gupta IV. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 2011;118:5126-9
   PubMed Web of Science ®Google Scholar
• Osterborg A, Martin JSD, Jiri M, Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL. ASCO; 2012
   Google Scholar
• Ferrajoli A, O'Brien S, Wierda W, Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial. ASH; 2011
   Google Scholar
• Teichman ML, Viet QH, Efficacy of Ofatumumab and High-Dose Methylprednisolone for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts; 2011. p. 118
   Google Scholar
• Spaner DE. Oral high-dose glucocorticoids and Ofatumumab in fludarabine-resistant Chronic Lymphocytic Leukemia. Leukemia 2012;26:1144-5
   PubMed Web of Science ®Google Scholar
• Flinn IW, Harwin WN, Macias-Pérez IM, A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. ASH Annual Meeting Abstracts; 2011. p. 118
   Google Scholar
• Wierda WG, Kipps TJ, Durig J, Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011;117:6450-8
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Clive SZ, Lanasa MC, Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL. ASH Annual Meeting Abstracts; 2011. p. 118
   Google Scholar
• Owen C, Stewart DA. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther 2012;12:343-51
   PubMed Web of Science ®Google Scholar
• Sehn LH, Assouline SE, Stewart DA, A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012;119:5118-25
   PubMed Web of Science ®Google Scholar
• Valentin G, Kirsten F, Raymonde B, Chemoimmunotherapy with Chlorambucil and the Type II CD20-Antibody GA101 In Patients with Chronic Lymphocytic Leukemia and Comorbidity: results of the Run-In Phase of the CLL11 (BO21004) Trial [abstract]. Blood 2010;116:1387
   Google Scholar
• Cartron G, Morschhauser F, Thieblemont C, Results from a phase II study of obinutuzumab (GA101) monotherapy in relapsed/refractory chronic lymphocytic leukemia (CLL). European Hematology Association Annual Congress [abstract]. Haematologica 2011;96(s2):0101a
   Google Scholar
• Goldenberg DM, Rossi EA, Stein R, Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009;113:1062-70
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Leonard JP, Fayad L, Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol 2009;27:3346-53
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Marlton P, Vitolo U, Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010;21:1870-6
   PubMed Web of Science ®Google Scholar
• Castro JE, Sandoval-Sus JD, Bole J, Rassenti L. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048-53
   PubMed Web of Science ®Google Scholar